Next Article in Journal
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations
Next Article in Special Issue
Peptide Vaccine: Progress and Challenges
Previous Article in Journal
Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus
Previous Article in Special Issue
Pleurocidin Peptide Enhances Grouper Anti-Vibrio harveyi Immunity Elicited by Poly(lactide-co-glycolide)-Encapsulated Recombinant Glyceraldehyde-3-phosphate Dehydrogenase
Open AccessReview

Therapeutic Vaccine Strategies against Human Papillomavirus

Immunotherapy and -prevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
*
Author to whom correspondence should be addressed.
Vaccines 2014, 2(2), 422-462; https://doi.org/10.3390/vaccines2020422
Received: 9 April 2014 / Revised: 16 May 2014 / Accepted: 27 May 2014 / Published: 13 June 2014
(This article belongs to the Special Issue Peptide Vaccine)
High-risk types of human papillomavirus (HPV) cause over 500,000 cervical, anogenital and oropharyngeal cancer cases per year. The transforming potential of HPVs is mediated by viral oncoproteins. These are essential for the induction and maintenance of the malignant phenotype. Thus, HPV-mediated malignancies pose the unique opportunity in cancer vaccination to target immunologically foreign epitopes. Therapeutic HPV vaccination is therefore an ideal scenario for proof-of-concept studies of cancer immunotherapy. This is reflected by the fact that a multitude of approaches has been utilized in therapeutic HPV vaccination design: protein and peptide vaccination, DNA vaccination, nanoparticle- and cell-based vaccines, and live viral and bacterial vectors. This review provides a comprehensive overview of completed and ongoing clinical trials in therapeutic HPV vaccination (summarized in tables), and also highlights selected promising preclinical studies. Special emphasis is given to adjuvant science and the potential impact of novel developments in vaccinology research, such as combination therapies to overcome tumor immune suppression, the use of novel materials and mouse models, as well as systems vaccinology and immunogenetics approaches. View Full-Text
Keywords: human papillomavirus (HPV); therapeutic vaccination; cancer immunotherapy; epitopes; cytotoxic T cells (CTL); T helper cells (Th); cervical cancer; peptide vaccination; nanoparticles (NPs); DNA vaccination; dendritic cell (DC) vaccination; vector-based vaccination; adjuvants human papillomavirus (HPV); therapeutic vaccination; cancer immunotherapy; epitopes; cytotoxic T cells (CTL); T helper cells (Th); cervical cancer; peptide vaccination; nanoparticles (NPs); DNA vaccination; dendritic cell (DC) vaccination; vector-based vaccination; adjuvants
MDPI and ACS Style

Khallouf, H.; Grabowska, A.K.; Riemer, A.B. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines 2014, 2, 422-462. https://doi.org/10.3390/vaccines2020422

AMA Style

Khallouf H, Grabowska AK, Riemer AB. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines. 2014; 2(2):422-462. https://doi.org/10.3390/vaccines2020422

Chicago/Turabian Style

Khallouf, Hadeel; Grabowska, Agnieszka K.; Riemer, Angelika B. 2014. "Therapeutic Vaccine Strategies against Human Papillomavirus" Vaccines 2, no. 2: 422-462. https://doi.org/10.3390/vaccines2020422

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop